⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NGNE News
Neurogene, Inc. Common Stock
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
NGNE
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
NGNE
Form 8-K
sec.gov
NGNE
Neurogene Inc. Announces Pricing of $125 Million Public Offering
businesswire.com
NGNE
Neurogene Inc. Announces Proposed Public Offering
businesswire.com
NGNE
Form 8-K
sec.gov
NGNE
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
businesswire.com
NGNE
Form 8-K
sec.gov
NGNE
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
businesswire.com
NGNE
Form 8-K
sec.gov
NGNE